Event submissions
Published
10.3390/PCMS-08960 (registering DOI) This submission belongs to the session 3. Advanced Nanomaterials and Nanotechnology of the event First Poster Competition on Materials Science
Published date
08 Jan, 2021
Citation
Kamil Rahme, Nadim Mitri, Giulio Fracasso, Esther Ghanem, Synthesis, Integrity, and Biocompatibility of scFvD2B Coated Gold Nanoparticles in Human Blood, in Proceedings of First Poster Competition on Materials Science, 20 January 2021, MDPI: Basel, Switzerland, doi: 10.3390/PCMS-08960
Share
Email
FaceBook
Twitter
Linkedin
Synthesis, Integrity, and Biocompatibility of scFvD2B Coated Gold Nanoparticles in Human Blood
'%3e%3cpath%20d='M12.6647%2010.9104C12.4176%2010.325%2012.0589%209.7933%2011.6088%209.34485C11.16%208.89511%2010.6283%208.53653%2010.0432%208.28891C10.038%208.28629%2010.0327%208.28498%2010.0275%208.28236C10.8437%207.69282%2011.3743%206.73252%2011.3743%205.64907C11.3743%203.85423%209.92005%202.40002%208.12522%202.40002C6.33038%202.40002%204.87618%203.85423%204.87618%205.64907C4.87618%206.73252%205.40677%207.69282%206.22296%208.28367C6.21772%208.28629%206.21248%208.2876%206.20724%208.29022C5.62031%208.53783%205.09365%208.89287%204.64167%209.34616C4.19192%209.79496%203.83334%2010.3266%203.58573%2010.9117C3.34247%2011.4846%203.21128%2012.0987%203.19925%2012.721C3.1989%2012.735%203.20135%2012.7489%203.20646%2012.7619C3.21157%2012.7749%203.21924%2012.7868%203.22901%2012.7968C3.23877%2012.8068%203.25045%2012.8148%203.26334%2012.8202C3.27623%2012.8256%203.29007%2012.8284%203.30406%2012.8284H4.09012C4.14776%2012.8284%204.19362%2012.7825%204.19493%2012.7262C4.22113%2011.7148%204.62726%2010.7676%205.34519%2010.0497C6.08802%209.30686%207.07452%208.89811%208.12522%208.89811C9.17592%208.89811%2010.1624%209.30686%2010.9052%2010.0497C11.6232%2010.7676%2012.0293%2011.7148%2012.0555%2012.7262C12.0568%2012.7839%2012.1027%2012.8284%2012.1603%2012.8284H12.9464C12.9604%2012.8284%2012.9742%2012.8256%2012.9871%2012.8202C13%2012.8148%2013.0117%2012.8068%2013.0214%2012.7968C13.0312%2012.7868%2013.0389%2012.7749%2013.044%2012.7619C13.0491%2012.7489%2013.0515%2012.735%2013.0512%2012.721C13.0381%2012.0947%2012.9084%2011.4856%2012.6647%2010.9104ZM8.12522%207.90243C7.52388%207.90243%206.95792%207.66793%206.53214%207.24215C6.10636%206.81636%205.87185%206.2504%205.87185%205.64907C5.87185%205.04773%206.10636%204.48177%206.53214%204.05599C6.95792%203.63021%207.52388%203.3957%208.12522%203.3957C8.72655%203.3957%209.29252%203.63021%209.7183%204.05599C10.1441%204.48177%2010.3786%205.04773%2010.3786%205.64907C10.3786%206.2504%2010.1441%206.81636%209.7183%207.24215C9.29252%207.66793%208.72655%207.90243%208.12522%207.90243Z'%20fill='%235D1EE1'/%3e%3c/g%3e%3c/svg%3e)
Nadim Mitri 1
Kamil Rahme 2
Giulio Fracasso 3
Esther Ghanem 1
1. Department of Sciences, Faculty of Natural and Applied Sciences, Notre Dame University, Lebanon
2. Department of Sciences, Chairperson, Faculty of Natural and Applied Sciences, Notre Dame University, Lebanon
3. Department of Pathology and Diagnostics, University of Verona, Verona, Italy
Abstract
Keywords
gold nanoparticles
prostate cancer
PSMA
D2B antibody
scFvD2B antibody
polyethylene glycol (PEG)